Octave Bioscience: Precision Care Company Extends $30 Million Series B Funding Round
Summary
This funding round will further accelerate commercialization efforts to bring Octaves multimodal solution to more multiple sclerosis patients.The company offers a complete precision care solution that combines blood biomarkers, expanded imaging capabilities, and clinical insights for a comprehensive view of the patient, including disease activity levels and disease progression. And these objective insights provide providers, payers, pharma, and patients with the tools needed to measure better, monitor, and more effectively manage these conditions.Commercially launched late last year, Octave is in use in multiple MS Centers of Excellence, academic centers, and high-volume independent clinics nationwide. The company is also committed to building collaborations and partnerships over time in a broad range of neurodegenerative diseases, including Parkinsons and Alzheimers.The strategic investor mix from across the ecosystem demonstrates the value and support in the Octave solution and its ability to improve the patient care paradigm in neurodegenerative diseases.The strength and breadth of our investment partners illustrate the impact our solution has across the entire healthcare ecosystem physicians, payers, pharma, and most importantly, patients. We appreciate our forward-thinking investors that recognize and value our strategy and approach, and support this important mission.We are impressed with Octaves comprehensive solution and its ability to help address the immense unmet need for patients with neurodegenerative diseases. By offering an end-to-end solution which optimizes and personalizes care, Octave is revolutionizing the way MS is treated and managed.